2. Search Result
Search Result
Results for "

IL-1β secretion

" in MedChemExpress (MCE) Product Catalog:

44

Inhibitors & Agonists

7

Natural
Products

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-101860
    GIBH-130
    3 Publications Verification

    		 Interleukin Related Neurological Disease
    GIBH-130 is an effective inhibitor of neuroinflammation. GIBH-130 significantly suppresses the IL-1β secretion by activated microglia (IC50=3.4 nM).
    GIBH-130
  • HY-W1000105
    Geranial

    (E)-3,7-Dimethylocta-2,6-dienal

    		 TNF Receptor Interleukin Related NOD-like Receptor (NLR) Inflammation/Immunology
    Geranial ((E)-3,7-Dimethylocta-2,6-dienal) is a derivative of geraniol with anti-inflammatory activity. Geranial can inhibit the secretion of TNF-α and IL-6 in macrophages. Furthermore, Geranial also inhibits the secretion of IL-1β mediated by the NLRP-3 inflammasome .
    Geranial
  • HY-162333
    BAL-0028

    		NOD-like Receptor (NLR) Interleukin Related Inflammation/Immunology
    BAL-0028 is a reversible inhibitor of NLRP3 activation with an IC50 value of 25 nM. BAL-0028 binds closely to the NACHT domain of the NLRP3 with KD values of 104-123 nM. BAL-0028 can inhibit the secretion of IL-1β and has anti-inflammatory activity .
    BAL-0028
  • HY-N6927
    Isoforskolin

    Coleonol B

    		 TNF Receptor Interleukin Related Inflammation/Immunology
    Isoforskolin is the principle active component of C. forskohlii native to China. Isoforskolin reduces the secretion of lipopolysaccharide (LPS)-induced cytokines, namely TNF-α, IL-1β, IL-6 and IL-8, in human mononuclear leukocytes. Isoforskolin acts as an anti-inflammatory agent for the treatment of Lyme arthritis .
    Isoforskolin
  • HY-164765
    NLRP3-IN-56

    		NOD-like Receptor (NLR) Inflammation/Immunology
    NLRP3-IN-56 (compound 062) is a NLRP3 inhibitor. NLRP3-IN-56 potently inhibits the level of IL-1β secretion by THP-1 cells with an IC50 of 9.7 nM. NLRP3-IN-56 can be used for the study of NLRP3-mediated symptoms and/or diseases .
    NLRP3-IN-56
  • HY-176452
    NLRP3 agonist 3

    		Cancer
    NLRP3 agonist 3 is an antibody-drug conjugate (ADC). NLRP3 agonist 3 is a NLRP3 agonist that induces IL-1β secretion in primary human monocytes. NLRP3 agonist 3 can be used in cancer research .
    NLRP3 agonist 3
  • HY-173046
    NLRP3-IN-71

    		NOD-like Receptor (NLR) Interleukin Related Neurological Disease Inflammation/Immunology
    NLRP3-IN-71 (Compound 19) is a BBB-permeable, orally active and selective NLRP3 inhibitor that can inhibit IL-1β secretion. NLRP3-IN-71 can be used for the research of neurodegenerative diseases .
    NLRP3-IN-71
  • HY-156340
    Anti-inflammatory agent 58

    		Interleukin Related Inflammation/Immunology
    Anti-inflammatory agent 58 is an anti-inflammatory agent. Anti-inflammatory agent 58 inhibits IL-1β with an IC50 of 1.08 μM. Anti-inflammatory agent 58 decreases pro-inflammatory gene expression, protein secretion, and NF-κB phosphorylation .
    Anti-inflammatory agent 58
  • HY-156342
    Anti-inflammatory agent 59

    		Interleukin Related Inflammation/Immunology
    Anti-inflammatory agent 59 is an anti-inflammatory agent. Anti-inflammatory agent 58 inhibits IL-1β with an IC50 of 2.28 μM. Anti-inflammatory agent 58 decreases pro-inflammatory gene expression, protein secretion, and NF-κB phosphorylation .
    Anti-inflammatory agent 59
  • HY-130480
    Fructose-arginine

    		AIM2 Inflammation/Immunology
    Fructose-arginine, an amino-sugar, is an AIM2 inflammasome activation inhibitor. Fructose-arginine attenuates the secretion of IL-1β, IL-18, and caspase-1, and Asc pyroptosome formation and Gsdmd cleavage resulting from AIM2 inflammasome activation .
    Fructose-arginine
  • HY-153261
    NLRP3-IN-17

    		NOD-like Receptor (NLR) Inflammation/Immunology
    NLRP3-IN-17 is a potent, selective and orally active NLRP3 inflammasome inhibitor with an IC50 value of 7 nM. NLRP3-IN-17 significantly inhibits NLRP3 dependent IL-1β secretion in mice and can be used for chronic inflammatory diseases research .
    NLRP3-IN-17
  • HY-156121
    NLRP3-IN-20

    		NOD-like Receptor (NLR) Inflammation/Immunology Cancer
    NLRP3-IN-20 (compound 11) is an orally available inhibitor of the NLRP3 inflammasome with an IC50 of 25 nM for IL-1β secretion. NLRP3-IN-20 has excellent pharmacokinetic properties and demonstrated significant efficacy in models of non-alcoholic steatohepatitis, fatal septic shock, and colitis .
    NLRP3-IN-20
  • HY-14644B
    Apilimod hydrochloride

    STA 5326 hydrochloride; LAM-002A (free base) hydrochloride; AIT-101 hydrochloride

    		 NOD-like Receptor (NLR) Infection Inflammation/Immunology
    Apilimod (STA 5326) hydrochloride is a PIKFYVE kinase inhibitor that promotes NLRP3 inflammatory vesicle activation and IL-1β secretion. Apilimod hydrochloride has been shown to inhibit host cell proteases, which may prevent viral invasion but also block antiviral immune responses, potentially exacerbating immunosuppression in COVID-19.
    Apilimod hydrochloride
  • HY-155463
    NLRP3-IN-25

    		NOD-like Receptor (NLR) Interleukin Related Inflammation/Immunology
    NLRP3-IN-25 (compound 32) is an orally available NLRP3 inhibitor with anti-inflammatory activity. NLRP3-IN-25 attenuates renal injury in doxorubicin-induced glomerulonephritis in mice. NLRP3-IN-25 inhibits IL-1β secretion in THP-1 cells with an IC50 of 21 nM .
    NLRP3-IN-25
  • HY-N6927R
    Isoforskolin (Standard)

    		TNF Receptor Interleukin Related Inflammation/Immunology
    Isoforskolin (Standard) is the analytical standard of Isoforskolin. This product is intended for research and analytical applications. Isoforskolin is the principle active component of C. forskohlii native to China. Isoforskolin reduces the secretion of lipopolysaccharide (LPS)-induced cytokines, namely TNF-α, IL-1β, IL-6 and IL-8, in human mononuclear leukocytes. Isoforskolin acts as an anti-inflammatory agent for the treatment of Lyme arthritis .
    Isoforskolin (Standard)
  • HY-134000
    Emodic acid

    NSC624610

    		 p38 MAPK NF-κB ERK JNK VEGFR MMP Cancer
    Emodic acid (NSC624610) is an anthraquinone compound isolated from A. microcarpus, which can inhibit the proliferation of cancer cells by inhibiting the activity of NF-κB. Emodic acid can also inhibit the phosphorylation of p38, ERK and JNK, the secretion of tumor-promoting cytokines IL-1β and IL-6, and the expression of VEGF and MMP, thereby inhibiting the invasion and migration potential of cancer cells .
    Emodic acid
  • HY-B2176R
    ATP (Standard)

    		Endogenous Metabolite Metabolic Disease Inflammation/Immunology
    ATP (Standard) is the analytical standard of ATP. This product is intended for research and analytical applications. ATP (Adenosine 5'-triphosphate) is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation . In Vitro: ATP (5 mM; 1 hour) co-treatment with LPS (1 μg/mL) has a synergistic effect on the activation of the NLRP3 inflammasome in HGFs .
    ATP (2 mM; 0.5-24 hours) induces secretion of IL-1β, KC and MIP-2 from BMDMs in a caspase-1 activation-dependent manner .
    ATP promotes neutrophil chemotaxis in vitro .
    In Vivo: ATP (50 mg/kg; i.p.) protects mice against bacterial infection in vivo .
    ATP induces the secretion of IL-1β, KC and MIP-2 and neutrophils recruitment in vivo .
    ATP (Standard)
  • HY-B1081
    Oxidopamine hydrochloride
    25+ Cited Publications

    6-Hydroxydopamine Hydrochloride

    		 Dopamine Receptor Autophagy Mitophagy COX PGE synthase Interleukin Related p38 MAPK Apoptosis Caspase Neurological Disease Cancer
    Oxidopamine (6-OHDA) hydrochloride is an antagonist of the neurotransmitter dopamine. Oxidopamine hydrochloride is a widely used neurotoxin and selectively destroys dopaminergic neurons. Oxidopamine hydrochloride promotes COX-2 activation, leading to PGE2 synthesis and pro-inflammatory cytokine IL-1β secretion. Oxidopamine hydrochloride can be used for the research of Parkinson’s disease (PD), attention-deficit hyperactivity disorder (ADHD), and Lesch-Nyhan syndrome .
    Oxidopamine hydrochloride
  • HY-B1081A
    Oxidopamine hydrobromide
    25+ Cited Publications

    6-Hydroxydopamine hydrobromide; 6-OHDA hydrobromide

    		 Dopamine Receptor Autophagy Mitophagy COX PGE synthase Interleukin Related p38 MAPK Apoptosis Caspase Neurological Disease Cancer
    Oxidopamine (6-OHDA) hydrobromide is an antagonist of the neurotransmitter dopamine. Oxidopamine hydrobromide is a widely used neurotoxin and selectively destroys dopaminergic neurons. Oxidopamine hydrobromide promotes COX-2 activation, leading to PGE2 synthesis and pro-inflammatory cytokine IL-1β secretion. Oxidopamine hydrobromide can be used for the research of Parkinson’s disease (PD), attention-deficit hyperactivity disorder (ADHD), and Lesch-Nyhan syndrome .
    Oxidopamine hydrobromide
  • HY-B0026
    Ceftiofur hydrochloride
    3 Publications Verification

    		 Antibiotic Bacterial NF-κB p38 MAPK TNF Receptor Interleukin Related Infection
    Ceftiofur hydrochloride is a cell wall synthesis inhibitor that targets bacterial penicillin-binding proteins (PBPs) and has anti-inflammatory effects in endotoxemia. Ceftiofur hydrochloride exerts bactericidal effects by inhibiting the synthesis of bacterial cell wall peptidoglycan, leading to bacterial cell lysis. Ceftiofur hydrochloride also inhibits the activation of NF-κB and MAPKs, thereby reducing the secretion of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 .
    Ceftiofur hydrochloride
  • HY-N7102
    Ceftiofur
    3 Publications Verification

    		 Antibiotic Bacterial NF-κB p38 MAPK TNF Receptor Interleukin Related Infection
    Ceftiofur is a cell wall synthesis inhibitor that targets bacterial penicillin-binding proteins (PBPs) and has anti-inflammatory effects in endotoxemia. Ceftiofur exerts bactericidal effects by inhibiting the synthesis of bacterial cell wall peptidoglycan, leading to bacterial cell lysis. Ceftiofur also inhibits the activation of NF-κB and MAPKs, thereby reducing the secretion of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 .
    Ceftiofur
  • HY-B0898
    Ceftiofur sodium
    3 Publications Verification

    sodium ceftiofur

    		 Antibiotic Bacterial NF-κB p38 MAPK TNF Receptor Interleukin Related Infection
    Ceftiofur sodium is a cell wall synthesis inhibitor that targets bacterial penicillin-binding proteins (PBPs) and has anti-inflammatory effects in endotoxemia. Ceftiofur sodium exerts bactericidal effects by inhibiting the synthesis of bacterial cell wall peptidoglycan, leading to bacterial cell lysis. Ceftiofur sodium also inhibits the activation of NF-κB and MAPKs, thereby reducing the secretion of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 .
    Ceftiofur sodium
  • HY-B0240
    Disulfiram
    85+ Cited Publications

    Tetraethylthiuram disulfide; TETD

    		 Aldehyde Dehydrogenase (ALDH) Interleukin Related Pyroptosis Apoptosis Cuproptosis Metabolic Disease Cancer
    Disulfiram (Tetraethylthiuram disulfide) is a specific inhibitor of aldehyde-dehydrogenase (ALDH1), used for the treatment of chronic alcoholism by producing an acute sensitivity to alcohol. Disulfiram inhibits gasdermin D (GSDMD) pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells. Disulfiram, a copper ion carrier, with Cu 2+ increases intracellular ROS levels and induces cuproptosis .
    Disulfiram
  • HY-170233
    NLRP3-IN-75

    		NOD-like Receptor (NLR) Interleukin Related NF-κB Inflammation/Immunology
    NLRP3-IN-75 is an orally active NLRP3 inhibitor. NLRP3-IN-75 suppresses IL-1β secretion (IC50 = 23 nM). NLRP3-IN-75 selectively inhibits NLRP3 activation by disrupting inflammasome assembly without affecting NLRC4 or AIM2 inflammasomes. NLRP3-IN-75 exhibits superior efficacy in acute peritonitis, diabetic kidney disease and IBD models .
    NLRP3-IN-75
  • HY-N14780
    Pochonin D

    (+)-Pochonin D

    		 HSP Interleukin Related Enterovirus Infection Inflammation/Immunology Cancer
    Pochonin D ((+)-Pochonin D) is an inhibitor of heat shock protein 90 (Hsp90) with antiviral and anti-inflammatory activities. Pochonin D inhibits Hsp90, affecting the homeostasis, folding, and assembly processes of viral proteins, reducing the replication ability of the virus. Pochonin D reduces the infiltration of inflammatory cells and the secretion of inflammatory cytokines such as TNF-α and IL-1β, alleviating the inflammatory response. Pochonin D is promising for research of Human rhinoviruses (HRV) infections and cancers .
    Pochonin D
  • HY-173416
    Anti-inflammatory agent 100

    		NF-κB p38 MAPK ERK JNK Inflammation/Immunology
    Anti-inflammatory agent 100 (Compound (+)-4S-23) is an anti-inflammatory agent. Anti-inflammatory agent 100 inhibits MAPK and NF-κB signaling, and also inhibits NF-κB pathway by suppressing the phosphorylation of IκB-α and blocking nuclear translocation of phosphorylated p65. Anti-inflammatory agent 100 inhibits NO production (IC50: 0.5 μM) and TNF-α, IL-6, IL-1β secretion .
    Anti-inflammatory agent 100
  • HY-B0240R
    Disulfiram (Standard)

    Tetraethylthiuram disulfide (Standard); TETD (Standard)

    		 Reference Standards Aldehyde Dehydrogenase (ALDH) Interleukin Related Pyroptosis Apoptosis Cuproptosis Metabolic Disease Cancer
    Disulfiram (Standard) is the analytical standard of Disulfiram. This product is intended for research and analytical applications. Disulfiram (Tetraethylthiuram disulfide) is a specific inhibitor of aldehyde-dehydrogenase (ALDH1), used for the treatment of chronic alcoholism by producing an acute sensitivity to alcohol. Disulfiram inhibits gasdermin D (GSDMD) pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells. Disulfiram + Cu 2+ increases intracellular ROS levels triggering apoptosis of ovarian cancer stem cells [1-6].
    Disulfiram (Standard)
  • HY-173180
    5-LOX-IN-8

    		Lipoxygenase Interleukin Related TNF Receptor IFNAR Inflammation/Immunology
    5-LOX-IN-8 is a 5-LOX inhibitor with anti-inflammatory activity. 5-LOX-IN-8 suppresses IL-6, IL-1β, TNF-α and IFN-γ in macrophages and reduces IL-8 secretion in SW480 cells. 5-LOX-IN-8 reduces disease activity in a DSS colitis model. 5-LOX-IN-8 can be used for research of inflammatory bowel disease (IBD) .
    5-LOX-IN-8
  • HY-162116
    TLR7 agonist 18

    		Toll-like Receptor (TLR) Inflammation/Immunology Cancer
    TLR7 agonist 18 (Compound 21a) is a selective Toll-like receptor 7 (TLR7) agonist with an EC50 of 7.8 μM. TLR7 agonist 18 is not cytotoxic to hTLR7 cotransfected HEK293 cell lines and can induce the secretion of several cytokines, including IL-1β, IL-12p70, IL-8, and TNF-α. TLR7 agonist 18 can be used in vaccine, asthma, allergy and anti-cancer research .
    TLR7 agonist 18
  • HY-112137
    Trehalose-6,6'-dibehenate

    		Caspase Interleukin Related MyD88 Inflammation/Immunology
    Trehalose-6,6'-dibehenate is an orally active glycolipid. Trehalose-6,6'-dibehenate activates Mincle and inflammasome, inducing IL-1β secretion in a caspase activity-dependent manner. Trehalose-6,6'-dibehenate exerts a Myd88-dependent adjuvant activity. Trehalose-6,6'-dibehenate induces Th-1/Th-17 immune responses .
    Trehalose-6,6'-dibehenate
  • HY-168935
    Anti-inflammatory agent 95

    		NO Synthase TNF Receptor Interleukin Related Inflammation/Immunology
    Anti-inflammatory agent 95 (Compound 2e) is an anti-inflammatory agent that exhibits the most potent anti-inflammatory activity in LPS (HY-D1056)-induced RAW 264.7 mouse macrophages. It significantly inhibits the production of NO, with an IC50 of 8.8 μM, and reduces the secretion of TNF-α and IL-1β, with inhibition rates reaching 60% and over 90%, respectively, at a concentration of 100 μM. Anti-inflammatory agent 95 holds promise for research in the field of inflammatory diseases .
    Anti-inflammatory agent 95
  • HY-171589
    NLRP3-IN-77

    		NOD-like Receptor (NLR) Interleukin Related Inflammation/Immunology Cancer
    NLRP3-IN-77 (Compound 7n) is a potent NLRP3 inflammasome inhibitor. NLRP3-IN-77 inhibits the viability of THP-1 cells with an IC50 value of 5.36 nM. NLRP3-IN-77 can effectively reduce the secretion of interleukin-1β (IL-1β) and interleukin-18 (IL-18). NLRP3-IN-77 is promising for research of diseases related to the abnormal activation of the NLRP3 inflammasome, such as cancer and inflammatory diseases .
    NLRP3-IN-77
  • HY-N7102R
    Ceftiofur (Standard)

    		Antibiotic Bacterial NF-κB p38 MAPK TNF Receptor Interleukin Related Infection
    Ceftiofur (Standard) is the analytical standard of Ceftiofur (HY-N7102). This product is intended for research and analytical applications. Ceftiofur is a cell wall synthesis inhibitor that targets bacterial penicillin-binding proteins (PBPs) and has anti-inflammatory effects in endotoxemia. Ceftiofur exerts bactericidal effects by inhibiting the synthesis of bacterial cell wall peptidoglycan, leading to bacterial cell lysis. Ceftiofur also inhibits the activation of NF-κB and MAPKs, thereby reducing the secretion of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 .
    Ceftiofur (Standard)
  • HY-B0898R
    Ceftiofur sodium (Standard)

    sodium ceftiofur (Standard)

    		 Antibiotic Bacterial NF-κB p38 MAPK TNF Receptor Interleukin Related Infection
    Ceftiofur sodium (Standard) is the analytical standard of Ceftiofur sodium (HY-B0898). This product is intended for research and analytical applications. Ceftiofur sodium is a cell wall synthesis inhibitor that targets bacterial penicillin-binding proteins (PBPs) and has anti-inflammatory effects in endotoxemia. Ceftiofur sodium exerts bactericidal effects by inhibiting the synthesis of bacterial cell wall peptidoglycan, leading to bacterial cell lysis. Ceftiofur sodium also inhibits the activation of NF-κB and MAPKs, thereby reducing the secretion of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 .
    Ceftiofur sodium (Standard)
  • HY-B0026R
    Ceftiofur hydrochloride (Standard)

    		Antibiotic Bacterial NF-κB p38 MAPK TNF Receptor Interleukin Related Infection
    Ceftiofur hydrochloride (Standard) is the analytical standard of Ceftiofur hydrochloride (HY-B0026). This product is intended for research and analytical applications. Ceftiofur hydrochloride is a cell wall synthesis inhibitor that targets bacterial penicillin-binding proteins (PBPs) and has anti-inflammatory effects in endotoxemia. Ceftiofur hydrochloride exerts bactericidal effects by inhibiting the synthesis of bacterial cell wall peptidoglycan, leading to bacterial cell lysis. Ceftiofur hydrochloride also inhibits the activation of NF-κB and MAPKs, thereby reducing the secretion of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 .
    Ceftiofur hydrochloride (Standard)
  • HY-B0898S
    Ceftiofur-d3 sodium

    		Isotope-Labeled Compounds Antibiotic Bacterial NF-κB p38 MAPK TNF Receptor Interleukin Related Infection
    Ceftiofur-d3 sodium is deuterium labeled Ceftiofur sodium (HY-B0898). Ceftiofur sodium is a cell wall synthesis inhibitor that targets bacterial penicillin-binding proteins (PBPs) and has anti-inflammatory effects in endotoxemia. Ceftiofur sodium exerts bactericidal effects by inhibiting the synthesis of bacterial cell wall peptidoglycan, leading to bacterial cell lysis. Ceftiofur sodium also inhibits the activation of NF-κB and MAPKs, thereby reducing the secretion of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 .
    Ceftiofur-d3 sodium
  • HY-152670
    JC2-11
    1 Publications Verification

    		 NOD-like Receptor (NLR) AIM2 Inflammation/Immunology
    JC2-11 is an inhibitor of inflammatory corpuscles. JC2-11 inhibits domain-containing protein NLRC 4, absent in melanoma 2 (AIM 2) and non-canonical (NC) inflammatory corpuscles. JC2-11 reduces the secretion of caspase-1 (p20), the cleavage of gasdermin D (GSDMD), and the releases of IL-1β and lactate dehydrogenases (LDH) in inflammatory bodies. JC2-11 inhibits the activation of inflammatory bodies by destroying the production of reactive oxygen species and the activity of caspase-1 .
    JC2-11
  • HY-13453
    BAY 11-7082
    Maximum Cited Publications
    343 Publications Verification

    BAY 11-7821

    		 IKK Deubiquitinase Autophagy Apoptosis NF-κB Inflammation/Immunology Cancer
    BAY 11-7082 is an IκBα phosphorylation and NF-κB inhibitor. BAY 11-7082 selectively and irreversibly inhibits the TNF-α-induced phosphorylation of IκB-α, and decreases NF-κB and expression of adhesion molecules. BAY 11-7082 inhibits ubiquitin-specific protease USP7 and USP21 (IC50=0.19, 0.96 μM, respectively). BAY 11-7082 inhibits gasdermin D (GSDMD) pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells .
    BAY 11-7082
  • HY-154919
    DC-Y13-27
    4 Publications Verification

    		 YTHDF FOXO MMP Pyroptosis Interleukin Related Endocrinology Cancer
    DC-Y13-27 is a DC-Y13 derivative and YTHDF2 inhibitor (KD: 37.9 μM). DC-Y13-27 inhibits YTHDF2, restores FOXO3 and TIMP1 protein levels, and reduces MMP1/3/7/9 expression. DC-Y13-27 induces Pyroptosis and increases IL-1β secretion. DC-Y13-27 reduces intervertebral disc degeneration and enhances the response to radiotherapy in colon cancer and melanoma. DC-Y13-27 has antitumor activity against breast cancer .
    DC-Y13-27
  • HY-W013579
    (S)-(+)-Carvone

    D-​Carvone

    		 SOD Reactive Oxygen Species Interleukin Related NOD-like Receptor (NLR) Caspase Apoptosis Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    (S)-(+)-Carvone is an orally active natural product. (S)-(+)-Carvone increases the activity of antioxidant enzymes (SOD, CAT) and ROS, reduces the levels of oxidative stress markers (MDA, AChE), reduces the secretion of proinflammatory cytokines (IL-1β, IL-4, IL-6, IL-10), and downregulates NLRP3. (S)-(+)-Carvone increases the activities of caspase-8, -9 and -3. (S)-(+)-Carvone induces apoptotic death. (S)-(+)-Carvone has antimanic-like effect, liver protection and anticancer activity against skin cancer. (S)-(+)-Carvone improves memory and arthritis .
    (S)-(+)-Carvone
  • HY-W013579R
    (S)-(+)-Carvone (Standard)

    		Others Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    (S)-(+)-Carvone (Standard) is the analytical standard of (S)-(+)-Carvone. This product is intended for research and analytical applications. (S)-(+)-Carvone is an orally active natural product. (S)-(+)-Carvone increases the activity of antioxidant enzymes (SOD, CAT) and ROS, reduces the levels of oxidative stress markers (MDA, AChE), reduces the secretion of proinflammatory cytokines (IL-1β, IL-4, IL-6, IL-10), and downregulates NLRP3. (S)-(+)-Carvone increases the activities of caspase-8, -9 and -3. (S)-(+)-Carvone induces apoptotic death. (S)-(+)-Carvone has antimanic-like effect, liver protection and anticancer activity against skin cancer. (S)-(+)-Carvone improves memory and arthritis .
    (S)-(+)-Carvone (Standard)
  • HY-154830
    Lysophosphatidylcholine C19:0

    1-Nonadecanoyl-2-hydroxy-sn-glycero-3-phosphocholine

    		 Others Others
    Lysophosphatidylcholine C19:0 (1-Nonadecanoyl-2-hydroxy-sn-glycero-3-phosphocholine) is an acyl chain lipid. Lysophosphatidylcholine C19:0 increases IL-1beta secretion .
    Lysophosphatidylcholine C19:0
  • HY-172162
    LC-04-045

    		NEKs Interleukin Related Inflammation/Immunology
    LC-04-045 is a NEK7 (NIMA-related kinase 7) molecular glue degrader (MGD). LC-04-045 demonstrates potent activity of NEK7 degradation with a DC50 (half-maximal degradation) of 7 nM and a Dmax (maximum degradation) of 90% in MOLT-4 cells. LC-04-045 displays high selectivity for NEK7 across the proteome. LC-04-045 degrades NEK7 mediated by the ubiquitin-proteasome system (UPS) and relies on the glycine 57 (G57)-containing degron motif in NEK7. LC-04-045 effectively inhibits secretion of IL-1β and IL-18 with IC50s of 33.03 nM and 32.99 nM, respectively. LC-04-045 is potential for inflammatory diseases research .
    LC-04-045
  • HY-101448
    TMI-1

    WAY-171318

    		 MMP Apoptosis Interleukin Related TNF Receptor Caspase Infection Neurological Disease Inflammation/Immunology Cancer
    TMI-1 (WAY-171318) inhibits TNF converting enzyme (TACE) (IC50 of 8.4 nM), ADAM-TS-4, ADAM-17 and various MMPs with oral activity. TMI-1 significantly suppresses the secretion of TNF-α , alleviating collagen-induced arthritis in mice. TMI-1 inhibits cancer cell proliferation, induces apoptosis through a caspase-dependent pathway. TMI-1 also reverses TRPV1 upregulation and lowers the levels of inflammatory factors (TNF-α、IL-1β、IL-6) in nerve cells, protecting against paclitaxel-induced neurotoxicity. TMI-1 leads to changes in pro-atherogenic lipoprotein profiles, but does not affect the progression of early lesions .
    TMI-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: